Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company focused on developing bioengineered human tissues, has announced a registered direct offering of 25 million shares of its common stock at a price of $0.80 per share. The offering is expected to generate approximately $20 million in gross proceeds, which will be utilized to fund the commercialization of its product, Symvess, particularly in the vascular trauma indication, and to support ongoing development activities, including the upcoming read-out of Phase 3 results in hemodialysis. The offering is anticipated to close on or about March 20, 2026, pending customary closing conditions. Titan Partners Group LLC is acting as the sole placement agent for this offering. The company has filed a prospectus supplement with the SEC, which will be available on the SEC's website. This offering follows a previous effective shelf registration statement filed in September 2025, allowing Humacyte to raise capital efficiently as it continues to advance its innovative therapies.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.